Stocktoria
Equillium, Inc. EQ
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-10-12
Chart by TradingView
1/9
Piotroski F — financial health
-12.18
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | $41.1M | $36.1M | $15.8M | — |
| Operating income | -$23.6M | -$8.3M | -$14.5M | -$62.1M | -$37.8M |
| Net income | -$22.4M | -$8.1M | -$13.3M | -$62.4M | -$39.1M |
| Operating cash flow | -$22.7M | -$19.0M | -$21.8M | -$8.7M | -$32.1M |
| Free cash flow | -$22.8M | -$19.1M | -$21.8M | -$9.0M | -$32.1M |
| Total assets | $31.9M | $25.6M | $50.5M | $78.4M | $85.4M |
| Total liabilities | $3.3M | $6.5M | $28.0M | $46.5M | $18.9M |
| Shareholders' equity | $28.6M | $19.1M | $22.6M | $31.9M | $66.5M |
| Ratios | |||||
| Operating margin | — | -20.1% | -40.2% | -393.9% | — |
| Net margin | — | -19.6% | -37.0% | -396.1% | — |
| FCF margin | — | -46.5% | -60.5% | -57.2% | — |
| Return on assets | -70.2% | -31.5% | -26.4% | -79.6% | -45.7% |
| Return on equity | -78.3% | -42.3% | -59.1% | -195.4% | -58.7% |
| Debt / equity | — | — | — | 0.10× | 0.13× |
| Current ratio | 10.58 | 3.93 | 1.79 | 2.40 | 9.35 |
| Revenue growth | — | 13.9% | 129.0% | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 656,964 | $1.3M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.18 (distress)
- Working capital / assets 0.881
- Retained earnings / assets -6.78
- EBIT / assets -0.741
- Equity / liabilities 8.692
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001746466 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.